Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie’s choice for patients with relapsed refractory multiple myeloma

Click to increase image sizeClick to decrease image size

Funding

This paper was not funded.

Declaration of Interest

H Hashmi declares that they are on the advisory board for Janssen, Bristol-Myers Squibb, and Sanofi. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

A peer reviewer on this manuscript has received advisory board and honoraria from Celgene/BMS and Janssen. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.